Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.
Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA; Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Domènech E, et al. Among authors: hinojosa j. Aliment Pharmacol Ther. 2004 Dec;20(11-12):1347-52. doi: 10.1111/j.1365-2036.2004.02288.x. Aliment Pharmacol Ther. 2004. PMID: 15606397 Free article.
Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
Hinojosa J, Gomollón F, García S, Bastida G, Cabriada JL, Saro C, Ceballos D, Peñate M, Gassull MA; Spanish Scientific Group on Crohn's Disease and Ulcerative Colitis. Hinojosa J, et al. Aliment Pharmacol Ther. 2007 Feb 15;25(4):409-18. doi: 10.1111/j.1365-2036.2006.03232.x. Aliment Pharmacol Ther. 2007. PMID: 17269996 Free article. Clinical Trial.
Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.
Casanova MJ, Chaparro M, Nantes Ó, Benítez JM, Rojas-Feria M, Castro-Poceiro J, Huguet JM, Martín-Cardona A, Aicart-Ramos M, Tosca J, Martín-Rodríguez MDM, González-Muñoza C, Mañosa M, Leo-Carnerero E, Lamuela-Calvo LJ, Pérez-Martínez I, Bujanda L, Hinojosa J, Pajares R, Argüelles-Arias F, Pérez-Calle JL, Rodríguez-González GE, Guardiola J, Barreiro-de Acosta M, Gisbert JP; EVODIS Study Group*. Casanova MJ, et al. Among authors: hinojosa j. Aliment Pharmacol Ther. 2021 Jun;53(12):1277-1288. doi: 10.1111/apt.16361. Epub 2021 May 7. Aliment Pharmacol Ther. 2021. PMID: 33962482
[Budesonide and inflammatory bowel disease].
Gomollón F, Hinojosa J, Nos P. Gomollón F, et al. Among authors: hinojosa j. Gastroenterol Hepatol. 1999 Dec;22(10):525-32. Gastroenterol Hepatol. 1999. PMID: 10650668 Review. Spanish. No abstract available.
[Budesonide in inflammatory bowel disease: a meta-analysis].
Nos P, Hinojosa J, Gomollón F, Ponce J. Nos P, et al. Among authors: hinojosa j. Med Clin (Barc). 2001 Jan 20;116(2):47-53. doi: 10.1016/s0025-7753(01)71716-2. Med Clin (Barc). 2001. PMID: 11181269 Review. Spanish.
[Recommendations for the use of infliximab (Remicade) in Crohn's disease. GETECCU 2001].
Domènech E, Esteve-Comas M, Gomollón F, Hinojosa J, Obrador A, Panés J, Gassull MA; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Domènech E, et al. Among authors: hinojosa j. Gastroenterol Hepatol. 2002 Mar;25(3):162-9. doi: 10.1016/s0210-5705(02)79012-2. Gastroenterol Hepatol. 2002. PMID: 11864540 Spanish. No abstract available.
434 results